Why Hims & Hers Health Stock Is Plummeting Today
Hims & Hers will no longer be able to sell generic "compounded" versions, a key driver of its recent success. The U.S. Food and Drug Administration (FDA) removed semaglutide injection products like the blockbuster drugs Ozempic and Wegovy from its shortage list.
Hims, Hers Stock and Preventive healthcare
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
UnitedHealth declines following a report that the Justice Department has been investigating the company’s Medicare billing ...
Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...
Shares of Novo Nordisk (NVO) are up 6% in pre-market trading after a FDA drug shortage notice indicated that a shortage of several versions of ...
Hims & Hers Health shares jumped some 20% to a record high on Wednesday following the announcement that it acquired lab ...
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...
1don MSN
The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.
BofA raised the firm’s price target on Hims & Hers to $21 from $18 and keeps an Underperform rating on the shares. The firm increased Q4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback